We make pharmaceutical innovations from known molecular entities. Our pipeline drugs are based on a rationale for fast clinical development, IP-protection, and commercial viability.
About Us
PDFE Pharma Innovations FZCO is a joint venture between India based Paaree Institute and Swedish based VidiLife CRA. Our combined skill set allow us to make pharmaceutical innovations from known molecular entities based on unmet patient needs, recent research, and intellectual property rights. We focus our innovation on drugs with high chance for commercial success rather than limiting ourselves to a disease domain. Pharmaceutical development from known molecular entities typically benefits from an accomplished preclinical development and a well documented safety profile. New drugs in this category can come to market with shorter lead time, at lower risk, and lower cost.
Pipeline
Our current pipeline include patented innovations for Irritable Bowel Syndrome (IBS), Androgenetic Alopecia (Hairloss), Acne, Rosacea, Ulcerative Colitis and Atopic Dermatitis (Eczema). In 2025, additional patents for Hirsutism (Excessive hair growth), Psoriasis and Onychomycosis (Nail fungus) were filed. The pipeline is expanding from an overall assessment of the market, patient needs, recent research, and intellectual property rights. This gives our drug concepts a strong foundation for streamlined clinical development and high chance of commercial success. For an in-depth personal presentation of our pipeline and collaboration model, please reach out to us in the “Contact Us” form.
IBEKET
IBEKET (PDFE-2302) is developed to meet the need for efficient symptom relief in Irritable Bowel Syndrome (IBS). Patient satisfaction with current treatments is only 20%, and as low as 3.6% in doctors for prescription alternatives. IBEKET aims at a pathological mechanism not previously targeted in IBS and that is the culprit in all subsets of the disease (IBS-D, IBS-C, and IBS-M). Besides acting normalizing on bowel habits, IBEKET is assessed to provide significant relief from bloating, flatulence, and sense of incomplete evacuation. With 10% suffering from IBS globally, IBEKET has the potential to capture a significant share of a market that is expected to reach $2.0 B in 2026 (7MM). PDFE Pharma patented IBEKET in May 2023 and entered a co-development agreement with AAMBAL Pharmaceuticals in May 2025. Agreement milestones include prototype development, GMP manufacturing of clinical study drug, phase 1/POC studies, and global IP. Licensing discussions will be open in the meantime.
NEOPILI
NEOPILI (PDFE-2304) is a topical treatment for androgenetic alopecia (male pattern hair loss). Androgenetic alopecia affects 80% of men and 50% of women, with few advances in treatment options since the FDA approval of Minoxidil in 1988. In addition to stimulating hair growth, we expect NEOPILI to have a rejuvenating effect on hair color and quality, taking hair loss treatment to a new level. In an AGA mouse model, the histology report demonstrated superiority over Minoxidil 5%, with +31.6% higher follicle density, 82.3% greater hair length, and +43.5% greater hair diameter. A Phase 2A study is ongoing (NCT07011485). The treatment market for androgenetic alopecia reached a value of $5.9 B in 2022 (7MM) and is expected to grow at a CAGR of 5.6% from 2023 to 2033. PDFE Pharma patented NEOPILI in September 2023 and entered a co-development agreement with STERIN Labs in April 2024. Agreement milestones include prototype development, GMP manufacturing of the clinical study drug, Phase 2A/POC studies, and global IP protection.
ZINEAC
ZINEAC (PDFE-2305) is a topical treatment for Acne Vulgaris (Acne). Acne affects 9.4% of the global population, making it the eighth most prevalent disease worldwide. The mainstay therapy with retinoids and benzoyl peroxide comes with dry, irritated and peeling skin. Moreover, treatments with antibiotics is increasingly deprecated due to resistance ranging from 10-73% in acneic bacterial strains. ZINEAC aims to provide a highly tolerable treatment beyond the challenge of bacterial resistance. With dual action it targets the bacterial imbalance as well as inflammation in mild and moderate acne. ZINEAC will undergo proof of concept studies also for Perioral Dermatitis and Rosacea, increasing chances for commercial success. The global Acne treatment market was valued at $9.7 B in 2022 with a compound annual growth rate (CAGR) of 4.8% during 2023-2032. PDFE Pharma patented ZINEAC in September 2023 and entered a co-development agreement with STERIN Labs in April 2024. Agreement milestones include prototype development, GMP manufacturing of clinical study drug, phase 1/POC studies, and global IP. Licensing discussions will be open in the meantime.
ATOLOR
ATOLOR (PDFE-2301) is a first-line ”Ease & Prevent” monotherapy for adults and children with mild to moderate Atopic Dermatitis (eczema). This patient group constitutes 95% of all eczema patients in which 60-70% are dissatisfied with current treatments. ATOLOR targets the need for a highly tolerable, short- and long-term monotherapy, reducing the burden of treatment discomforts and complexity while maintaining remission. Successful therapy at the first step of the treatment ladder has potential for a domino effect on all treatment steps, with less need for topical and systemic corticosteroids, antibiotics, immunosuppressants, etc. ATOLOR is expected to prove the high safety required for prescription-free drugs and thus targets a low competition segment on a market valued at $6.4 B (7 MM). PDFE Pharma patented ATOLOR in May 2023 with ongoing formulation development and intellectual property optimization. We welcome investors and collaborators in financial participation of clinical trial supply manufacturing and early stage clinical trials.
PILODUCE
PILODUCE (PDFE‑2501) is a topical treatment for hirsutism and unwanted hair growth. Following epilation by wax or epilator, PILODUCE is applied as a lotion to suppress hair regrowth in a semi‑permanent manner. PILODUCE has demonstrated robust efficacy in three independent mouse studies, with most endpoints reaching statistical significance despite the small sample size. No mice exhibited signs of skin irritation with the optimized formulation. These findings highlight PDFE‑2501 as a promising candidate for novel and convenient hair growth suppression with potential applications in both medical and cosmetic settings. The global (7MM) market value for hirsutism (medical treatment) was estimated at $3.47 B in 2025. The cosmetic (non‑medical) market for unwanted hair growth was valued at $5.0–7.0 B. PDFE Pharma patented PILODUCE in October 2025, with ongoing formulation development and intellectual‑property optimization. A co‑development agreement with STERIN Labs was signed the same month. Agreement milestones include prototype development, GMP manufacturing of the clinical study drug, Phase 1 / POC studies, and global IP expansion.
Investors & Partners
We collaborate with investors or partners from the pharmaceutical industry to develop our pipeline drugs from phase 1 and beyond. When teaming with an investor we are able manage the development cycle to the point of market approval. When teaming with the pharmaceutical industry the partner may choose to close a licencing agreement or co-develop in a joint venture with us. Our collaboration flexibility give investors and partners the chance to seamlessly incorporate our drug concepts into their existing organisation and business model.
Our Team
PDFE Pharma Innovations FZCO is a joint venture between India based Paaree Institute and Swedish based VidiLife CRA. Paaree Institute was founded by Praba, an experienced pharma industry professionals with a PhD in pharmaceutical development. Paaree Institute is engaged in pharmaceutical development and intellectual property rights. VidiLife CRA was founded by Fredrik with a background as doctor in clinical settings, research, and bioinformatics. VidiLife implements in-silico drug innovation and CRA services. Our combined skill set allow us to manage the full drug develop cycle, from idea to market approval. We are expanding our board of clically and research active physicians with an interest in androgenic allopecia (AGA), acne, and irritable bowel syndrom (IBS). Feel free to reach out to us via LinkeIn or the contact form bellow.
Medical Doctor
Fredrik Enqvist
Pharmacist
Prabakaran D, PhD
Contact Us
PDFE PHARMA INNOVATIONS – FZCO
DSO-IFZA, IFZA Properties,
Dubai Silicon Oasis, Dubai, UAE